Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240022/S004

Evolysse Injectable Hyaluronic Acid

Symatese · Decision date Dec 19, 2025

FDA DECISIONP240022/S004

What did the FDA approve?

FDA records P240022/S004 as a supplement to PMA P240022, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Dec 19, 2025.

FDA approval order statement

Approval for a design change to the syringe plunger rod for the Evolysse injectable hyaluronic acid gels approved under P240022
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
General, Plastic Surgery
Decision date
Dec 19, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P240022/S004
Regulatory pathway
PMA supplement
Applicant
Symatese
Product code
LMH
Decision code
APPR
Decision date
Dec 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Symatese
Product code
LMH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P240022/S001 · Related supplement

    EVOLYSSE FORM and EVOLYSSE SMOOTH

  2. P240022/S004 received

    Application receipt date recorded by FDA.

  3. P240022/S004 · FDA decision

    Real-Time Process

  4. P240022/S005 · Related supplement

    Evolysse Smooth; Evolysse Form

Timeline entries are records held by MedtechLedger for P240022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240022

Product / regulatory recordCompanyPathwayDecision dateSource
SymatesePMA supplementSep 3, 2025FDA
Evolysse FORMP240022/S003
SymatesePMA supplementDec 18, 2025FDA
SymatesePMA supplementFeb 27, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Symatese

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Zi Les Troques, Chaponost, 69630

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records